anti-CD7 universal chimeric antigen receptor T-cell therapy

Anti-CD7 universal chimeric antigen receptor T-cell therapy (anti-CD7 U-CAR-T) is an investigational allogeneic (off-the-shelf) adoptive cell therapy targeting the CD7 antigen, which is highly expressed in T-cell and NK-cell malignancies. Developed by the Hematology Department of the Second Affiliated Hospital of the Army Medical University, the therapy utilizes CRISPR/Cas9 technology to genetically modify healthy donor-derived T cells. Specifically, the CD7 gene is knocked out to prevent CAR-T cell fratricide (self-killing), and the T-cell receptor alpha constant (TRAC) gene is deleted to minimize the risk of graft-versus-host disease (GvHD). This 'universal' approach allows for immediate treatment without the need for patient-specific manufacturing. The therapy is primarily being studied as a bridge to hematopoietic stem cell transplantation (HSCT) for patients with relapsed or refractory CD7-positive T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL).

Other names

anti-CD7 universal CAR-Tanti-CD-7 universal CAR-Tanti-CD 7 universal CAR-TUCART7UCART-7UCART 7CD7-targeted universal CAR-T cellsCD-7-targeted universal CAR-T cellsCD 7-targeted universal CAR-T cells